Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…
Kamada Pharmaceuticals
(https://kamada.com) 📸 Data Snapshot: May 31, 2026Analyze the raw signals below. How would a machine score this business’s credibility?
Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.
🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Kamada – High Quality Pharmaceuticals – Kamada Pharmaceuticals (https://kamada.com)
Title
Kamada – High Quality Pharmaceuticals – Kamada Pharmaceuticals
H2 Latest Updates
H2 UPCOMING EVENT
H2 UPDATED COMPANY PRESENTATION
H2 PRODUCTS
H2 PIPELINE
H2 ALPHA-1 ANTITRYPSIN MECHANISM OF ACTION
H3 Committed to Alpha-1 Patients
H3 Supporting prevention of CMV disease after solid organ transplantation
H3 MORETHERAPEUTICFOCUSAREAS
NAV_HEADING_REPEATED_BODY_FOOTER Therapeutic Focus Areas – Kamada Pharmaceuticals (https://kamada.com/therapeutic-focus-areas/)
Title
Therapeutic Focus Areas – Kamada Pharmaceuticals
H1 Therapeutic Focus Areas
H2 Alpha-1 Antitrypsin Deficiency
H2 CMV Disease
H2 COVID-19
H2 Hepatitis B recurrence after liver transplantation
H2 Rabies
NAV_REPEATED_BODY_FOOTER Company Profile & Milestones – Kamada Pharmaceuticals (https://kamada.com/company-profile/)
Title
Company Profile & Milestones – Kamada Pharmaceuticals
H1 Company Profile & Milestones
H2 Kamada Milestones
NAV_REPEATED_FOOTER News – Kamada Pharmaceuticals (https://kamada.com/news-main/)
Title
News – Kamada Pharmaceuticals
H1 News
H3 Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
H3 Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
H3 Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
H3 Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
H3 Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
H3 Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
H3 Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026
H3 Kamada Provides 2026 Annual Guidance of $200 – $205 Million in Revenues and $50 – $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
H3 Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender
H3 Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://kamada.com) Kamada – High Quality Pharmaceuticals – Kamada Pharmaceuticals
EACH LIFE IS UNIQUE Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. READ MORE [IMG: Watch the video] [H2] Latest Updates Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year May. 13, 2026 Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026 May. 6, 2026 Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders Mar. 31, 2026 Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas Mar. 26, 2026 Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth Mar. 11, 2026 Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy Mar. 11, 2026 [IMG: Kamada to Present at WTC Transplant Summit 2025:] [H2] UPCOMING EVENT Kamada to Present at WTC Transplant Summit 2025: Aug. 2 - 6, 2025San Francisco, CA USA [IMG: Company Presentation] [H2] UPDATED COMPANY PRESENTATION [H2] PRODUCTS Our proprietary platform technology and know-how allow us to extract and purify protein therapeutics from human plasma. OURPRODUCTS [H2] PIPELINE Kamada’s Inhaled AAT has the potential of becoming a transformational next- generation augmentation therapy for Alpha-1 Antitrypsin Deficiency patients. View Pipeline [H2] ALPHA-1 ANTITRYPSIN MECHANISM OF ACTION [IMG: Watch the video] The unique properties and demonstrated clinical safety of AAT, render it an attractive therapeutic candidate for various medical conditions. This video illustrates the mechanism of action of AAT, and its possible therapeutic effects. [H3] Committed to Alpha-1 Patients Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis. Read more [H3] Supporting prevention of CMV disease after solid organ transplantation Cytomegalovirus (CMV) is a common virus for people of all ages. It belongs to the Herpesviridae family and is highly evolved and adapted to humans. Read more [H3] MORETHERAPEUTICFOCUSAREAS
2568 chars
SUB-PAGE (https://kamada.com/therapeutic-focus-areas/) Therapeutic Focus Areas – Kamada Pharmaceuticals
Science [H1] Therapeutic Focus Areas [IMG: Alpha-1 Antitrypsin Deficiency] [H2] Alpha-1 Antitrypsin Deficiency Committed to Alpha-1 Patients Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis. READ MORE [IMG: CMV Disease] [H2] CMV Disease Supporting prevention of CMV disease after solid organ transplantation Cytomegalovirus (CMV) is a common virus for people of all ages. It belongs to the Herpesviridae family and is highly evolved and adapted to humans. READ MORE [IMG: COVID-19] [H2] COVID-19 Taking part in the fight against COVID-19 Over the past months, our lives have changed dramatically as a result of the Coronavirus (COVID-19) pandemic. COVID-19 is caused by the novel virus SARS-CoV-2. As new facts about the virus and the pandemic are revealed, the international scientific community, along with the pharmaceutical industry, are making tremendous efforts in order to combat the disease. […] READ MORE [IMG: Hepatitis B recurrence after liver transplantation] [H2] Hepatitis B recurrence after liver transplantation Hepatitis B is a liver infection caused by the hepatitis B virus. It is a major global health problem. Some people with hepatitis B are sick for only a few weeks (known as an “acute” infection). Some people, especially those who get infected in adulthood, can clear the virus from their bodies without treatment. Hepatitis […] READ MORE [IMG: Rabies] [H2] Rabies Helping to prevent one of the deadliest diseases in the world Rabies is a preventable infectious viral disease that is almost always fatal following the onset of clinical symptoms. In up to 99% of cases, domestic dogs are responsible for rabies virus transmission to humans. Yet, rabies can affect both domestic and wild animals. It is spread to people through bites or scratches, usually via saliva. […] READ MORE
2048 chars
SUB-PAGE (https://kamada.com/company-profile/) Company Profile & Milestones – Kamada Pharmaceuticals
About [H1] Company Profile & Milestones Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The company’s strategy is focused on driving profitable growth from current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical market. The company’s commercial products portfolio includes its developed and FDA approved products GLASSIA® and KEDRAB® as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM®, HEPAGAM B®, VARIZIG® and WINRHO®SDF. Kamada has additional four plasma-derived products which are registered in markets outside the U.S. Kamada distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia.
1113 chars
SUB-PAGE (https://kamada.com/news-main/) News – Kamada Pharmaceuticals
Investors & Media [H1] News 13 May. 2026 [H3] Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year Q1-2026 Revenue of $45.2 Million, up 3% Year-over-Year; Adjusted EBITDA of $11.6 Million, representing a Robust 26% Margin of Revenues; Net Income of $4.1 Million, up 4% Year-over-Year Underlying Demand for the Company’s Products Continues to Increase, Supporting the Company’s Expectation for a Significantly Stronger Remainder of 2026 Company Affirms 2026 Annual Guidance of $200 […] 6 May. 2026 [H3] Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026 REHOVOT, Israel, and HOBOKEN, NJ – May 6, 2026 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that it will release financial results for the first quarter ended March […] 31 Mar. 2026 [H3] Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders REHOVOT, Israel, and HOBOKEN, NJ – March 31, 2026 – Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the […] 26 Mar. 2026 [H3] Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas San Antonio Center Cleared to Commence Commercial Sales of Normal Source Plasma State of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full Capacity The Center is Structured to Collect Normal Source Plasma and Specialty Plasma, […] 11 Mar. 2026 [H3] Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy REHOVOT, Israel, and HOBOKEN, NJ – March 11, 2026 – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a cash dividend of $0.25 (approximately […] 11 Mar. 2026 [H3] Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth 2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year; Net Income of $20.2 Million, up 40% Year-over-Year Company Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Double-Digit Organic Growth Generated $25.5 Million […] 4 Mar. 2026 [H3] Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026 REHOVOT, Israel, and HOBOKEN, NJ – March 4, 2026 — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year […] 7 Jan. 2026 [H3] Kamada Provides 2026 Annual Guidance of $200 – $205 Million in Revenues and $50 – $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance 2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance 2026 Annual Guidance is Based Solely on Continued Organic Growth Company Continues to Focus on Securing New Business Development and M&A Transactions to Accelerate Long-Term Profitable Growth Kamada Affirms 2025 Guidance of $178 Million […] 18 Dec. 2025 [H3] Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender Company Awarded Extension to Existing Supply Tender Relating to its Portfolio of Four Specialty Plasma-Derived Products Supply Extension Secures Ongoing Sales of Approximately $5.0-$7.0 Million Per Year for the Period Between Q2-26 and Q1-28 Kamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Kamada Projects Double-Digit […] 8 Dec. 2025 [H3] Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026 Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDA Kamada Reiterates its 2025 Full-Year Revenue Guidance […] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
5351 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
20Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 5 | 0 |
| /therapeutic-focus-areas/ | 5 | 0 |
| /company-profile/ | 5 | 0 |
| /news-main/ | 5 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.kamada.com/",
"url": "https://www.kamada.com/",
"name": "Kamada - High Quality Pharmaceuticals - Kamada Pharmaceuticals",
"isPartOf": {
"@id": "https://www.kamada.com/#website"
},
"about": {
"@id": "https://www.kamada.com/#organization"
},
"datePublished": "2018-03-12T13:48:26+00:00",
"dateModified": "2025-07-16T13:25:44+00:00",
"breadcrumb": {
"@id": "https://www.kamada.com/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://www.kamada.com/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://www.kamada.com/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home"
}
]
},
{
"@type": "WebSite",
"@id": "https://www.kamada.com/#website",
"url": "https://www.kamada.com/",
"name": "Kamada Pharmaceuticals",
"description": "High Quality Pharmaceuticals",
"publisher": {
"@id": "https://www.kamada.com/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://www.kamada.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
},
{
"@type": "Organization",
"@id": "https://www.kamada.com/#organization",
"name": "Kamada Pharmaceuticals",
"url": "https://www.kamada.com/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://www.kamada.com/#/schema/logo/image/",
"url": "https://www.kamada.com/wp-content/uploads/2022/12/kamada-pharmaceuticals.png",
"contentUrl": "https://www.kamada.com/wp-content/uploads/2022/12/kamada-pharmaceuticals.png",
"width": 340,
"height": 130,
"caption": "Kamada Pharmaceuticals"
},
"image": {
"@id": "https://www.kamada.com/#/schema/logo/image/"
}
}
]
}
/therapeutic-focus-areas/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.kamada.com/therapeutic-focus-areas/",
"url": "https://www.kamada.com/therapeutic-focus-areas/",
"name": "Therapeutic Focus Areas - Kamada Pharmaceuticals",
"isPartOf": {
"@id": "https://www.kamada.com/#website"
},
"datePublished": "2018-03-12T13:31:13+00:00",
"dateModified": "2018-04-02T10:00:38+00:00",
"breadcrumb": {
"@id": "https://www.kamada.com/therapeutic-focus-areas/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://www.kamada.com/therapeutic-focus-areas/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://www.kamada.com/therapeutic-focus-areas/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.kamada.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Therapeutic Focus Areas"
}
]
},
{
"@type": "WebSite",
"@id": "https://www.kamada.com/#website",
"url": "https://www.kamada.com/",
"name": "Kamada Pharmaceuticals",
"description": "High Quality Pharmaceuticals",
"publisher": {
"@id": "https://www.kamada.com/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://www.kamada.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
},
{
"@type": "Organization",
"@id": "https://www.kamada.com/#organization",
"name": "Kamada Pharmaceuticals",
"url": "https://www.kamada.com/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://www.kamada.com/#/schema/logo/image/",
"url": "https://www.kamada.com/wp-content/uploads/2022/12/kamada-pharmaceuticals.png",
"contentUrl": "https://www.kamada.com/wp-content/uploads/2022/12/kamada-pharmaceuticals.png",
"width": 340,
"height": 130,
"caption": "Kamada Pharmaceuticals"
},
"image": {
"@id": "https://www.kamada.com/#/schema/logo/image/"
}
}
]
}
/company-profile/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.kamada.com/company-profile/",
"url": "https://www.kamada.com/company-profile/",
"name": "Company Profile & Milestones - Kamada Pharmaceuticals",
"isPartOf": {
"@id": "https://www.kamada.com/#website"
},
"datePublished": "2017-01-12T09:05:04+00:00",
"dateModified": "2023-01-03T15:09:26+00:00",
"breadcrumb": {
"@id": "https://www.kamada.com/company-profile/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://www.kamada.com/company-profile/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://www.kamada.com/company-profile/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.kamada.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Company Profile & Milestones"
}
]
},
{
"@type": "WebSite",
"@id": "https://www.kamada.com/#website",
"url": "https://www.kamada.com/",
"name": "Kamada Pharmaceuticals",
"description": "High Quality Pharmaceuticals",
"publisher": {
"@id": "https://www.kamada.com/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://www.kamada.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
},
{
"@type": "Organization",
"@id": "https://www.kamada.com/#organization",
"name": "Kamada Pharmaceuticals",
"url": "https://www.kamada.com/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://www.kamada.com/#/schema/logo/image/",
"url": "https://www.kamada.com/wp-content/uploads/2022/12/kamada-pharmaceuticals.png",
"contentUrl": "https://www.kamada.com/wp-content/uploads/2022/12/kamada-pharmaceuticals.png",
"width": 340,
"height": 130,
"caption": "Kamada Pharmaceuticals"
},
"image": {
"@id": "https://www.kamada.com/#/schema/logo/image/"
}
}
]
}
/news-main/
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.kamada.com/news-main/",
"url": "https://www.kamada.com/news-main/",
"name": "News - Kamada Pharmaceuticals",
"isPartOf": {
"@id": "https://www.kamada.com/#website"
},
"datePublished": "2018-03-16T06:50:32+00:00",
"dateModified": "2019-11-12T13:03:03+00:00",
"breadcrumb": {
"@id": "https://www.kamada.com/news-main/#breadcrumb"
},
"inLanguage": "en-US",
"potentialAction": [
{
"@type": "ReadAction",
"target": [
"https://www.kamada.com/news-main/"
]
}
]
},
{
"@type": "BreadcrumbList",
"@id": "https://www.kamada.com/news-main/#breadcrumb",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.kamada.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "News"
}
]
},
{
"@type": "WebSite",
"@id": "https://www.kamada.com/#website",
"url": "https://www.kamada.com/",
"name": "Kamada Pharmaceuticals",
"description": "High Quality Pharmaceuticals",
"publisher": {
"@id": "https://www.kamada.com/#organization"
},
"potentialAction": [
{
"@type": "SearchAction",
"target": {
"@type": "EntryPoint",
"urlTemplate": "https://www.kamada.com/?s={search_term_string}"
},
"query-input": {
"@type": "PropertyValueSpecification",
"valueRequired": true,
"valueName": "search_term_string"
}
}
],
"inLanguage": "en-US"
},
{
"@type": "Organization",
"@id": "https://www.kamada.com/#organization",
"name": "Kamada Pharmaceuticals",
"url": "https://www.kamada.com/",
"logo": {
"@type": "ImageObject",
"inLanguage": "en-US",
"@id": "https://www.kamada.com/#/schema/logo/image/",
"url": "https://www.kamada.com/wp-content/uploads/2022/12/kamada-pharmaceuticals.png",
"contentUrl": "https://www.kamada.com/wp-content/uploads/2022/12/kamada-pharmaceuticals.png",
"width": 340,
"height": 130,
"caption": "Kamada Pharmaceuticals"
},
"image": {
"@id": "https://www.kamada.com/#/schema/logo/image/"
}
}
]
}
Your Diagnosis
Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.
Information Density
0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence
0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof
0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint
0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority
0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score
0 / 100
Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)
These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.
Information Density
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Semantic Alignment
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Trust & Proof
Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Commodity Fingerprint
Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.
Identity & Authority
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.
B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS
Based on 784 businesses audited.
BS Detector
Medical Devices, Pharma & Biotech BS: Kamada Pharmaceuticals (kamada.com)
https://kamada.com
📍 Industry: Medical Devices, Pharma & Biotech
28
BS / 100
Kamada Pharmaceuticals provides a high-substance, low-BS digital presence that prioritizes regulatory and financial transparency over marketing fluff. It is a rare corporate site where the data in the ‘News’ section is more compelling and specific than the ‘About Us’ section. The low BS score is only slightly inflated by technical schema omissions and standard industry boilerplate.
Info Density
Power-words vs. Substance ratio.
4
13% BS
Semantic Coherence
Homepage promise vs. Sub-page reality.
1
5% BS
Trust & Proof
Verifiable evidence vs. Trust Theatre.
10
50% BS
Commodity Fingerprint
Detection of industry clichés/templates.
7
47% BS
Identity & Authority
Expert verifiability & Schema depth.
6
40% BS
Optimize the schema_json by adding sameAs links to SEC filings and major stock exchange listings to close the authority gap. Replace the generic review metadata with links to published, peer-reviewed studies for each flagship product. Add a specific H1 heading to the homepage to match the technical precision of the sub-pages. Link trade-named products directly to their official FDA prescribing information documents to provide a direct proof path.
The site is a perfect match for the Biopharmaceutical industry, specifically focusing on plasma-derived therapeutics. The content consistently references regulatory approvals, therapeutic areas like Alpha-1 Antitrypsin Deficiency, and clinical trial results.
“The score was primarily driven by the trust_theatre_flag and unverified review metadata (Trust and Proof pillar) and the lack of advanced sameAs schema (Identity and Authority). The Information Density and Semantic Coherence pillars scored near perfectly, reflecting a business that actually does what it says it does.”
Verified Analysis Date: May 31, 2026
© 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution
This training module utilizes a snapshot of public data from Kamada Pharmaceuticals, captured on May 31, 2026, to demonstrate how machine logic evaluates different types of business narratives.
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.
Notice to Kamada Pharmaceuticals: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.
Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://kamada.com to view the most current version of its content and learn from the source what this company is about and what it offers.